IP Library Granted Patent US 9,035,023
Granted Patent B2
US 9,035,023 · App. 12/921,209 · Granted May 19, 2015

Bombesin analog peptide antagonist conjugates

Inventors: Helmut Maecke (Lörrach, DE); Jean Claude Reubi (Wabern, CH); Rosalba Mansi (Münchenstein, CH)
Assignee: Piramal Imaging, SA
C07K7/086A61K51/088
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,035,023
App. No.
12/921,209
Granted
May 19, 2015
Kind
B2
Abstract

To provide a diagnostic and therapeutic medicament, a bombesin analog peptide antagonist conjugate is provided which has general Formula (I), wherein A is a metal chelator comprising at least one radionuclide metal, B is a spacer linked to N-terminal of C or a covalent bond and C is a bombesin analog peptide antagonist having a sequence as claimed, where further x is an integer from 1 to 3 and n is an integer from 1 to 6. [A-(B) n ] x —C  (I)

Claims (68)

1. A bombesin analog peptide antagonist conjugate having formula (I)

A-B-C  (I)

wherein

A is a metal chelator which is:

1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid,

and A contains a radionuclide metal conjugated thereto selected from the group consisting of:

a) 68 Ga,

b) 111 In,

c) 90 Y, and

d) 177 Lu,

B is a spacer linked to the N-terminal of C which is:

4-amino-1-carboxymethyl-piperidine,

and

C is a bombesin analog peptide antagonist of the following sequence:

D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH 2 .

2. The bombesin analog peptide antagonist conjugate according to claim 1 wherein the radionuclide metal for imaging is selected from the group consisting of:

68 Ga and 111 In.

3. The bombesin analog peptide antagonist conjugate according to claim 1 wherein the radionuclide metal for radiotherapy is selected from the group consisting of:

90 Y and 177 Lu.

4. The bombesin analog peptide antagonist conjugate of Formula (I′)

A′-B-C  (I′)

wherein

A′ is a metal chelator which is: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, and is free of a radionuclide metal,

B is a spacer linked to the N-terminal of C which is: 4-amino-1-carboxymethyl-piperidine, and

C is a bombesin analog peptide antagonist of the following sequence:

D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH 2 .

5. A pharmaceutical composition comprising any one of the bombesin analog peptide antagonist conjugates according to claim 1 .

6. A method comprising binding any one of the bombesin analog peptide antagonist conjugates according to claim 1 to a bombesin receptor.

7. A method for preparing any one of the bombesin analog peptide antagonist conjugates according to claim 1 , comprising:

radiochelating a bombesin analog peptide antagonist conjugate having Formula (I′)

A′-B-C  (I′)

wherein

A′ is included instead of A and has the same meaning as A except that it is a metal chelator free of radionuclide metal,

with a suitable radionuclide metal or metal atom.

8. A method for imaging bombesin receptors in a patient, comprising:

administering to a patient a radiopharmaceutical effective amount of a bombesin analog peptide antagonist conjugate according to claim 1 ; and

imaging the radionuclide metal in the patient.

9. A method according to claim 8 , wherein the bombesin receptor imaged is in GRP receptor expressing tumor cells, tumoral vessels or peritumoral vessels.

10. A method according to claim 9 , wherein said tumor cells refer to tumor cells from cancers that are selected from the group consisting of:

prostate cancer, including metastases,

breast cancer, including metastases,

gastrointestinal stromal tumors,

small cell lung carcinomas,

renal cell carcinomas,

gastroenteropancreatic neuroendocrine tumors,

head and neck squamous cell cancers,

neuroblastomas, and

oesophageal squamous cell carcinomas,

and wherein

said tumoral and peritumoral vessels refer to tumoral and peritumoral vessels from cancers that are selected from the group consisting of:

ovarian cancers,

endometrial cancers, and

pancreatic cancers.

11. A method for treating diseases, comprising administering a therapeutically effective amount of bombesin analog peptide antagonist conjugate according to claim 6 , and wherein the diseases are selected from the group consisting of:

prostate cancer, including metastases,

breast cancer, including metastases,

gastrointestinal stromal tumors,

small cell lung carcinomas,

renal cell carcinomas,

gastroenteropancreatic neuroendocrine tumors,

head and neck squamous cell cancers,

neuroblastomas, and

oesophageal squamous cell carcinomas.

12. A kit for the preparation of a radiotherapeutical agent or of a radiopharmaceutical imaging agent comprising a vial containing a predetermined quantity of the bombesin analog peptide antagonist conjugate according to claim 4 and an acceptable carrier, diluent, excipient or adjuvant for radiolabeling the agent with a metal chelator.

13. A method according to claim 6 , wherein the bombesin receptor is a gastrin releasing peptide receptor (GRP).

14. The bombesin analog peptide antagonist conjugate according to claim 1 , wherein the radionuclide metal for imaging is 68 Ga.

15. A bombesin analog peptide antagonist conjugate according to claim 1 , which is:

16. A bombesin analog peptide antagonist conjugate according to claim 4 , which is:

Assignments (2)
CHANGE OF NAME Recorded Sep 27, 2011
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 026978/0576 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2010
From: MAECKE, HELMUT; REUBI, JEAN CLAUDE; MANSI, ROSALBA
To: UNIVERSITAETSSPITAL BASEL; UNIVERSITAET BERN
Reel/Frame 025489/0349 →
Priority Claims (1)
EP 08075180 · Mar 7, 2008 · regional
Continuity (1)
Related Publication 20110097266A1 · Apr 28, 2011